US Top Rating Updates on 12/30: NFLX, IDYA, GNRC, AMTI and More

CFRA analyst Kenneth Leon double upgraded $Netflix (NFLX.US)$ to Buy from Sell with a price target of $310, up from $225. The analyst believes it "will be difficult for competitors to catch" Netflix, noting it is one of the few profitable streaming providers with global scale.

Capital One analyst Zegbeh Jallah initiated coverage of $IDEAYA Biosciences (IDYA.US)$ with an Overweight rating and $29 price target. Ideaya has "strong precision medicine capabilities," inclusive of a Synthetic Lethality Platform, said Jallah, who thinks the SL program IDE397 in Phase 1 development "could be a blockbuster."

Piper Sandler analyst Abbie Zvejnieks last night initiated coverage of $Skechers USA (SKX.US)$ with a Neutral rating and $42 price target. Skechers has "favorable secular tailwinds of comfort and convenience and a significant margin expansion opportunity," but the stock's current valuation is fair given the uncertain consumer spending environment, Zvejnieks tells investors in a research note.